Eton Pharmaceuticals Buys US, Canadian Rights To Zeneo Hydrocortisone Autoinjector

Eton Pharmaceuticals Inc ETON has acquired the U.S. and Canadian rights to Crossject's Zeneo hydrocortisone needleless autoinjector.
The product is under development as a rescue treatment for adrenal crisis.
Zeneo is a pre-filled, single-use device that propels medication through the skin in less than a tenth of a second.
Crossject holds more than 400 global patents on the device, including 24 issued in the U.S. extending as far as 2037.
Eton expects to submit a marketing application for the product to the FDA in 2023 and plans to request Orphan Drug Designation.
Under the terms of the agreement, Crossject will receive development and regulatory milestone payments from Eton of up to $5 million, commercial milestones of up to $6 million, and a 10% royalty on net sales of the product.
Crossject will be responsible for the management and expense of development, clinical, and manufacturing activities.
Eton will take care of all regulatory and commercial activities.
Yesterday, the FDA approved Rezipres (ephedrine hydrochloride injection) to treat hypotension occurring in the setting of anesthesia.
Price Action: ETON shares are down 1.46% at $6.73 during the premarket session on the last check Wednesday.